SARISSA CAPITAL MANAGEMENT LP
Q3 2021 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001577524
· CRD 167244
· SEC-registered investment adviser
$1.3B Reported Value Total
SARISSA CAPITAL MANAGEMENT LP reports 12 total accounts under management (AUM). There are 12 discretionary accounts valued at $1,325,147,037, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
7 funds
· $691.7M gross asset value
Hedge Fund: $691.7M
Source: Form ADV filed 2026-07-08
Reported value
$1.3B
Quarter over quarter
+3.2%
Holdings
10
Top-10 concentration
100.0%
Key People
Form ADV owners & control persons
Alexander John Denner
CHIEF EXECUTIVE OFFICER/CHIEF INVESTMENT OFFICER
Laura Tucker Schnaidt
CHIEF COMPLIANCE OFFICER & GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2021 13F record
Q3 2021 13F filing summary
| Period of report | September 30, 2021 |
|---|---|
| Filed | November 15, 2021 |
| Form | 13F-HR |
| Reported value | $1.3B |
| Positions | 10 |
| Change in reported value | +1.3% |
| New positions | 1 |
| Exited positions | 5 |
| Position turnover | 40.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
10 | $177.9M |
|
Q1 2026 13F
Filed May 15, 2026
|
9 | $157.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
9 | $222.9M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
8 | $180.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
7 | $154.4M |
|
Q1 2025 13F
Filed May 15, 2025
|
7 | $154.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
8 | $322.9M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
10 | $402.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
10 | $592.4M |
|
Q1 2024 13F
Filed May 15, 2024
|
10 | $571.6M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
9 | $648.9M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
11 | $742.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
11 | $1.0B |
|
Q1 2023 13F
Filed May 15, 2023
|
11 | $781.9M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
11 | $840.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
11 | $884.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
11 | $993.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
11 | $1.1B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
11 | $1.2B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
10 | $1.3B |
31 earlier quarters on file — choose one from the quarter menu above.
Top 10 holdings · Q3 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ALKS ALKERMES PLC | $407.5M | 31.99% |
| 2 | IRWD IRONWOOD PHARMACEUTICALS INC | $214.1M | 16.8% |
| 3 | GILD GILEAD SCIENCES INC | $207.3M | 16.27% |
| 4 | BIIB BIOGEN INC | $182.0M | 14.28% |
| 5 | INVA INNOVIVA INC | $110.5M | 8.68% |
| 6 | BCRX BIOCRYST PHARMACEUTICALS INC | $56.4M | 4.43% |
| 7 | AMRN AMARIN CORP PLC | $43.4M | 3.4% |
| 8 | MRSN MERSANA THERAPEUTICS INC | $40.5M | 3.18% |
| 9 | VOR VOR BIOPHARMA INC | $11.1M | 0.87% |
| 10 | RGLS REGULUS THERAPEUTICS INC | $1.3M | 0.1% |
Values as reported on the Q3 2021 Form 13F. Every position is in the holdings table below.